Literature DB >> 16544172

Proposal for mapping renal failure in Japan and its application for strategy to arrest endstage renal disease.

Takeshi Usami1, Genjiro Kimura.   

Abstract

Remarkable regional differences in the annual incidence of endstage renal disease (ESRD) was found within Japan, which has a relatively homogeneous ethnic composition. In addition, there existed no regional difference in the incidence of ESRD due to polycystic kidney disease, the major genetic disorder of the kidneys. These findings suggest that the presence of factors other than genetic disposition contribute to the differences. On the other hand, there were similar regional variations in the incidences of ESRD between two causes of ESRD: chronic glomerulonephritis and diabetic nephropathy. Because it is unlikely that the regional distribution of underlying disease incidence and the disease-specific progression rate would be similar for two different causes, this observation suggests that factors governing the progression rate, which operate commonly for all causes of ESRD but differ among regions, may play an important role in generating the regional differences. Finally, we examined regional differences in the amounts of inhibitors of the renin-angiotensin system used, especially angiotensin-converting enzyme (ACE) inhibitors, in our search for an explanation of the regional differences in ESRD dynamics. Among antihypertensive agents examined, only ACE inhibitors were negatively correlated with the annual incidence of ESRD. The renal protective effects of ACE inhibitors have been established by results with animal models of progressive nephropathy and by large-scale clinical trials. Our epidemiological results for Japan as a whole show the same protective effects still more convincingly from a different approach. It is not completely clear yet at present, however, how regional variations in the incidence of ESRD are generated. If we could identify in future the factors that contribute to the regional differences, strategies for the treatment of renal disease will become available from different angles. Thus, much effort will be encouraged for the further analysis of regional differences in ESRD dynamics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16544172     DOI: 10.1007/s10157-005-0404-5

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  47 in total

Review 1.  Regional variation in end-stage renal disease.

Authors:  Takeshi Usami; Rika Sato; Atsuhiro Yoshida; Genjiro Kimura
Journal:  Curr Opin Nephrol Hypertens       Date:  2002-05       Impact factor: 2.894

2.  The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease.

Authors:  Tazeen H Jafar; Paul C Stark; Christopher H Schmid; Svend Strandgaard; Anne-Lise Kamper; Giuseppe Maschio; Gavin Becker; Ronald D Perrone; Andrew S Levey
Journal:  Kidney Int       Date:  2005-01       Impact factor: 10.612

3.  Geographic variation in the incidence of treated end-stage renal disease.

Authors:  B Foxman; L H Moulton; R A Wolfe; K E Guire; F K Port; V M Hawthorne
Journal:  J Am Soc Nephrol       Date:  1991-12       Impact factor: 10.121

4.  End-stage renal disease in African-American and white men. 16-year MRFIT findings.

Authors:  M J Klag; P K Whelton; B L Randall; J D Neaton; F L Brancati; J Stamler
Journal:  JAMA       Date:  1997 Apr 23-30       Impact factor: 56.272

5.  Racial differences in the incidence of treatment for end-stage renal disease.

Authors:  S G Rostand; K A Kirk; E A Rutsky; B A Pate
Journal:  N Engl J Med       Date:  1982-05-27       Impact factor: 91.245

6.  Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.

Authors:  R Zatz; B R Dunn; T W Meyer; S Anderson; H G Rennke; B M Brenner
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

Review 7.  Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function.

Authors:  Murray Epstein; Vito M Campese
Journal:  Am J Kidney Dis       Date:  2005-01       Impact factor: 8.860

8.  Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States.

Authors:  Chi-Yuan Hsu; Feng Lin; Eric Vittinghoff; Michael G Shlipak
Journal:  J Am Soc Nephrol       Date:  2003-11       Impact factor: 10.121

Review 9.  Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease.

Authors:  B M Brenner; T W Meyer; T H Hostetter
Journal:  N Engl J Med       Date:  1982-09-09       Impact factor: 91.245

10.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.

Authors:  S Klahr; A S Levey; G J Beck; A W Caggiula; L Hunsicker; J W Kusek; G Striker
Journal:  N Engl J Med       Date:  1994-03-31       Impact factor: 91.245

View more
  3 in total

1.  Japanese subpopulation analysis of the RENAAL, the landmark trial, is welcomed by our society.

Authors:  Genjiro Kimura
Journal:  Clin Exp Nephrol       Date:  2006-09       Impact factor: 2.801

2.  Predicted prevalence in Japan of chronic kidney disease (CKD).

Authors:  Genjiro Kimura
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

3.  Environmental factors influencing the survival of chronic dialysis patients.

Authors:  Satoshi Ogata; Noriaki Yorioka
Journal:  Clin Exp Nephrol       Date:  2011-01-20       Impact factor: 2.801

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.